Epoetin Alfa

Epoetin alfa (rINN) ( /ɛˈpoʊ.ɨtɨn/) is human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28th of August 2007, it stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Epoetin is marketed under the trade names Procrit and Epogen. Its annual cost to U.S. patients is $8,447 per patient per year.

For several years, Epogen was the single most expensive drug paid for by U.S. Medicare. Dosing is controversial, and higher doses, to raise hematocrit to normal levels, are associated with higher risks of hospitalization, strokes and death.